Origin Sciences wins Cambridge Innovation Award for OriColâ„¢ sample collection device

Press Release: Origin Sciences wins Cambridge Innovation Award for Oricol sample collection device

23 September 2014 — London and Cambridge, UK —

Origin developed Oricol based on feedback from GI, Oncology and other experts that there exist major gaps in the current model of disease detection based on stool sampling. To address market need, Origin Sciences developed the novel Oricol sampler that allows physicians to easily and securely collect samples of the full rectal mucosa for a range of high-value screening tests and analyses. The product allows physicians and nurse practitioners access to key patient samples to be used in combination with a variety of screening modalities including genomic-based assays, morphology and chemical detection of cancers. Using the Oricol technology, Origin is developing a portfolio of assays and seeking collaborations to develop high-value diagnostic tests for the GI market. Origin’s first assay in development will identify a primary marker for IBD, calprotectin. Additional Origin and partnered assays will include tests based on gut microbiome and tests for colorectal cancer.

Oricol has a high level of patient acceptability and no preparation of the bowel is required. The sampling can be carried out by a trained healthcare professional within five minutes. The Oricol device offers a convenient, minimally invasive alternative to stool collection and provides a sample rich in cells, nucleic acids, proteins, mucus, microorganisms (gut microbiome) and some faecal matter.

Scientific Director at Origin Sciences, Dr Jodie Booth comments:

“We are thrilled to receive this award and to be recognised for our novel Oricol device, which has the potential to vastly improve the way clinical samples are taken for the diagnosis of GI diseases.”